An audit of treatment outcome in acromegalic patients attending our center at Bergamo, Italy

Pituitary

Volumn 11, Issue 1, 2008, Pages 1-11

  Attanasio, Roberto ^a   Montini, Marcella ^a   Valota, Monia ^b   Cortesi, Liana ^b   Barbò, Regina ^b   Biroli, Francesco ^b   Tonnarelli, Giampiero ^c   Albizzi, Mascia ^b   Testa, Rosa Miranda ^b   Pagani, Giorgio ^b  

^a IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c Ospedale di Legnano   (Italy)

Author keywords

Acromegaly; GH; IGF I; Neurosurgery; Somatostatinanalogs; Treatment

Indexed keywords

ANGIOPEPTIN; ARGININE; BROMOCRIPTINE; CABERGOLINE; CORTICOTROPIN; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; LONG ACTING DRUG; OCTREOTIDE; PEGVISOMANT; PROLACTIN; QUINAGOLIDE; SHORT ACTING DRUG; SOMATOMEDIN C; SOMATOSTATIN ANTIBODY; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISEASE CONTROL; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; FOLLOW UP; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HORMONE DETERMINATION; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS; HYPOPITUITARISM; ITALY; MAJOR CLINICAL STUDY; MALE; MICROADENOMA; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SEX DIFFERENCE; SEX RATIO; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 38649100355     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-007-0059-1     Document Type: Article

References (46)

1. Melmed S (2006) Acromegaly. N Engl J Med 355:2558-2573
2. Wright AD, Hill DM, Lowy C, Fraser TR (1970) Mortality in acromegaly. Q J Med 39:1-16
3. Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: Epidemiology, pathogenesis and management. Endocr Rev 25:102-152
4. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: A consensus statement. J Clin Endocrinol Metab 85:526-529
5. Bates AS, Van't Hoff W, Jones JM, Clayton RN (1993) An audit of outcome of treatment in acromegaly. Q J Med 86:293-299
6. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK (1994) Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41:95-102
7. Swearingen B, Barker FG, Katznelson L, Biller BMK, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419-3426
8. Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, Romijn JA, Roelfsema F (2004) Determinants of survival in treated acromegaly in a single center: Predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 89:2789-2796
9. Holdaway IM, Rajasoorya CR, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667-674
10. Kauppinen-Mäkelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E (2005) A Nationwide Survey of Mortality in Acromegaly. J Clin Endocrinol Metab 90:4081-4086
11. Dorin RI, Qualls CR, Crapo LM (2003) Diagnosis of adrenal insufficiency. Ann Int Med 139:194-204
12. Lopez-Schmidt I, Lahner H, Mann K, Petersenn S (2003) Diagnosis of adrenal insufficiency: Evaluation of the corticotropin-releasing hormone test and basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease. J Clin Endocrinol Metab 88:4193-4198
13. Ghigo E, Aimaretti G, Arvat E, Camanni F (2001) Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults. Endocrine 15:29-38
14. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: A cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91:4769-4775
15. Samani AA, Yakar S, LeRoith D, Brodt P (2007) The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev 28:20-47
16. American Association of Clinical Endocrinologists Acromegaly Guidelines Task Force (2004) Medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocr Pract 10:213-225
17. Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical "cure". Eur J Endocrinol 152:379-387
18. De P, Rees DA, Davies N et al (2003) Transsphenoidal surgery for acromegaly in Wales: Results based on stringent criteria of remission. J Clin Endocrinol Metab 88:3567-3572
19. Yamada S, Aiba T, Takada K, Ozawa Y, Shimizu T, Sawano S, Shishiba Y, Sano T (1996) Retrospective analysis of long-term surgical results in acromegaly: Preoperative and postoperative factors predicting outcome. Clin Endocrinol (Oxf) 45:291-298
20. Fahlbusch R, Honegger J, Buchfelder M (1992) Surgical management of acromegaly. Endocrinol Metab Clin North Am 21:669-692
21. Losa M, Mortini P, Urbaz L, Ribotto P, Castrignano T, Giovanelli M (2006) Presurgical treatment with somatostatin analogs in patients with acromegaly: Effects on the remission and complication rates. J Neurosurg 104:899-906
22. Colao AM, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G, Cozzi R (2006) Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 91:85-92
23. Biermasz NR, Pereira AM, Neelis KJ, Roelfsema F, Romijn JA (2006) Role of radiotherapy in the management of acromegaly. Exp Rev Endocrinol Metab 1:449-460
24. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry. Eur J Endocrinol 151:439-446
25. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS (2004) Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89:1613-1617
26. Minniti G, Traish D, Ashley S, Gonsalves A, Brada M (2005) Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: Update after an additional 10 years. J Clin Endocrinol Metab 90:800-804
27. Attanasio R, Epaminonda P, Motti, Giugni E, Ventrella L, Cozzi R, Farabola M, Loli P, Beck-Peccoz P, Arosio M (2003) Gamma-knife radiosurgery in acromegaly: A 4-year-follow-up study. J Clin Endocrinol Metab 88:3105-3131
28. Castinetti F, Taieb D, Kuhn JM, Chanson P, Tamura M, Jaquet P, Conte-Devolx B, Regis J, Dufour H, Brue T (2005) Outcome of gamma knife radiosurgery in 82 patients with acromegaly: Correlation with initial hypersecretion. J Clin Endocrinol Metab 90:4483-4488
29. Jaffe CA, Barkan AL (1992) Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 21:713-735
30. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A (1998) Cabergoline in the treatment of acromegaly: A study in 64 patients. J Clin Endocrinol Metab 83:374-378
31. Cozzi R, Attanasio R, Barausse M, Dallabonzana D, Orlandi P, DaRe N, Branca V, Oppizzi G, Gelli D (1998) Cabergoline treatment in acromegaly: a renewed role for dopamine agonist? Eur J Endocrinol 139:516-521
32. Newman CB (1999) Medical therapy for acromegaly. Endocrinol Metab Clin North Am 28:171-190
33. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D (2005) Long-acting somatostatin analog therapy of acromegaly: A meta-analysis. J Clin Endocrinol Metab 90:4465-4473
34. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88:3090-3098
35. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini A, Doneda P, Cortesi L, Pagani G (2006) Primary treatment of acromegaly with octreotide LAR: A long-term (up to 9 years) prospective study on its efficacy in the control of disease activity and on tumor shrinkage. J Clin Endocrinol Metab 91:1397-1403
36. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL (1998) Octreotide as primary treatment for acromegaly. J Clin Endocrinol Metab 83:3034-3040
37. Attanasio R, Baldelli R, Pivonello R, Grottoli S, Bocca L, Gasco V, Giusti M, Tamburrano G, Colao A, Cozzi R (2003) Lanreotide 60 mg, a new long-acting formulation: Effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab 88:5258-5265
38. Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JAH (2005) The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clin Endocrinol (Oxf) 62:282-288
39. Pokrajac A, Claridge AG, Shakoor SKA, Trainer PJ (2006) The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly. Eur J Endocrinol 154:267-274
40. Cozzi R, Attanasio R, Lodrini S, Lasio G (2004) Cabergoline addition to depot somatostatin analogs in resistant acromegalic patients: Efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 61:209-215
41. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177
42. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759
43. Parkinson C, Ryder WDJ, Trainer PJ, the Sensus Acromegaly Study Group (2001) The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. J Clin Endocrinol Metab 86:5240-5244
44. Parkinson C, Renehan AG, Ryder WD, O'Dwyer ST, Shalet SM, Trainer PJ (2002) Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly. Clin Endocrinol (Oxf) 57:59-64
45. Engström BE, Burman P, Karlsson FA (2002) Men with acromegaly need higher doses of octreotide than women. Clin Endocrinol (Oxf) 56:73-77
46. Cozzi R, Attanasio R, Grottoli S, Pagani G, Loli P, Gasco V, Pedroncelli AM, Montini M, Ghigo E (2004) GH and IGF-I levels in acromegalic patients during treatment with Somatostatin analogs: Should hormonal targets be lowered to assert a good control of the disease? J Endocrinol Invest 27:1040-1047